Pharmaceutical Manufacturing Handbook: Production and

More documents

Recommendations

Info

PHARMACEUTICAL MANUFACTURING HANDBOOK <strong>Production</strong> <strong>and</strong> Processes
Page 1: PHARMACEUTICAL MANUFACTURING HANDBO
Page 6 and 7: Copyright © 2008 by John Wiley & S
Page 8 and 9: vi CONTRIBUTORS Robert D. Arnold, T
Page 10 and 11: viii CONTRIBUTORS Iv á n Pe ñ uel
Page 12 and 13: x CONTENTS 3.2 Packaging and Labeli
Page 15: PREFACE This Handbook of Manufactur
Page 19 and 20: 1.1 BIOTECHNOLOGY - DERIVED DRUG PR
Page 21 and 22: INTRODUCTION 5 provide a suffi cien
Page 23 and 24: therapeutic potency, specifi city,
Page 25 and 26: Diffi culties in peroral delivery h
Page 27 and 28: tial. Therefore, the indication and
Page 29 and 30: TABLE 2 Continued Parameter Assesse
Page 31 and 32: ceutical stability program should a
Page 33 and 34: FORMULATION DEVELOPMENT 17 see when
Page 35 and 36: FORMULATION DEVELOPMENT 19 heat ter
Page 37 and 38: organisms, stability (shelf life),
Page 39 and 40: TABLE 3 Potential Degradative Mecha
Page 41 and 42: QUALITY BY DESIGN AND SCALE-UP 25 w
Page 43 and 44: QUALITY BY DESIGN AND SCALE-UP 27 p
Page 45 and 46: ACKNOWLEDGMENTS The authors would l
Page 47 and 48: REFERENCES 31 37. Berglund , M. , B
Page 49 and 50: 1.2 REGULATORY CONSIDERATIONS IN AP
Page 51 and 52: HISTORY OF BIOLOGICS REGULATION IN
Page 53 and 54:
HISTORY OF BIOLOGICS REGULATION IN
Page 55 and 56:
HISTORY OF BIOLOGICS REGULATION IN
Page 57 and 58:
TABLE 4 FDA Center Regulatory Respo
Page 59 and 60:
approved via a BLA under the PHSA a
Page 61 and 62:
LEGAL ARGUMENTS RELATED TO FOLLOW-O
Page 63 and 64:
SCIENTIFIC ISSUES RELATED TO FOLLOW
Page 65 and 66:
SCIENTIFIC ISSUES RELATED TO FOLLOW
Page 67 and 68:
albumin with polysorbate 80 and gly
Page 69 and 70:
PROPOSED REGULATORY PARADIGM: CASE
Page 71 and 72:
effi cacy for Genotropin. These dat
Page 73:
REFERENCES 57 21. Webber , K. ( 200
Page 76 and 77:
60 RADIOPHARMACEUTICAL MANUFACTURIN
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 115 and 116:
2.1 STERILE PRODUCT MANUFACTURING J
Page 117 and 118:
(FDA) in its 2004 Guideline on Ster
Page 119 and 120:
PROCESS SELECTION AND DESIGN 103 di
Page 121 and 122:
FACILITY DESIGN 105 is transfer int
Page 123 and 124:
FACILITY DESIGN 107 The formulation
Page 125 and 126:
FACILITY DESIGN 109 In large operat
Page 127 and 128:
FACILITY DESIGN 111 universal expec
Page 129 and 130:
FACILITY DESIGN 113 facilities equi
Page 131 and 132:
from manual compounding of small ba
Page 133 and 134:
2.1.5.4 Other Utilities The operati
Page 135 and 136:
STERILIZATION AND DEPYROGENATION 11
Page 137 and 138:
ENVIRONMENTAL CONTROL AND MONITORIN
Page 139 and 140:
ENVIRONMENTAL CONTROL AND MONITORIN
Page 141 and 142:
PRODUCTION ACTIVITIES 125 It is inc
Page 143 and 144:
PRODUCTION ACTIVITIES 127 Filling o
Page 145 and 146:
assembly/technique) using a growth
Page 147 and 148:
culminate in the incubation of the
Page 149 and 150:
REFERENCES REFERENCES 133 1. U.S. F
Page 151:
ADDITIONAL READINGS 135 Ljungvist ,
Page 155 and 156:
3.1 FROM PILOT PLANT TO MANUFACTURI
Page 157 and 158:
BACKGROUND 141 Pisano [3] discusses
Page 159 and 160:
T amb F3 F2 F1 Scale Scale Scale Ad
Page 161 and 162:
LABORATORY VESSELS AND REACTION CAL
Page 163 and 164:
LABORATORY VESSELS AND REACTION CAL
Page 165 and 166:
Drive nozzle face D FIGURE 4 C E 10
Page 167 and 168:
Overall U, English units 80 70 60 5
Page 169 and 170:
mCp/UA, min 28 27 26 25 24 23 22 21
Page 171 and 172:
control valve was on the inlet stre
Page 173 and 174:
3.1.6 SUMMARY In this chapter we ha
Page 175 and 176:
3.2 PACKAGING AND LABELING Maria In
Page 177 and 178:
PACKAGING MATERIALS 161 For these r
Page 179 and 180:
PACKAGING MATERIALS 163 3.2.2.2 Gla
Page 181 and 182:
PACKAGING MATERIALS 165 Rubber clos
Page 183 and 184:
PACKAGING MATERIALS 167 of the USP
Page 185 and 186:
PACKAGING MATERIALS 169 Topical del
Page 187 and 188:
PACKAGING MATERIALS 171 based topic
Page 189 and 190:
QUALITY CONTROL OF PACKAGING MATERI
Page 191 and 192:
Page 193 and 194:
TABLE 5 Chapter U.S. Pharmacopeia G
Page 195 and 196:
Page 197 and 198:
Topical Drug Products Topical dosag
Page 199 and 200:
IMPORTANCE OF PROPER PACKAGING AND
Page 201 and 202:
4. Require that vials containing me
Page 203 and 204:
8. A description of the scientifi c
Page 205 and 206:
The only warning that is necessary,
Page 207 and 208:
REGULATORY ASPECTS 191 Section 1451
Page 209 and 210:
include any term qualifying a unit
Page 211 and 212:
for the promulgation of any such re
Page 213 and 214:
Label Issuance and Control • Acce
Page 215 and 216:
REFERENCES 199 9. Aspinall , J. A.
Page 217 and 218:
3.3 CLEAN - FACILITY DESIGN, CONSTR
Page 219 and 220:
PLANNING FOR PROJECT SUCCESS 203 im
Page 221 and 222:
PLANNING FOR PROJECT SUCCESS 205 of
Page 223 and 224:
DESIGN OPTIONS 207 with clean - roo
Page 225 and 226:
TABLE 1 Room Grade f A g B C D E An
Page 227 and 228:
Clean Garment Storage Bench Air loc
Page 229 and 230:
DESIGN OPTIONS 213 FIGURE 4 Furnish
Page 231 and 232:
DESIGN OPTIONS 215 FIGURE 6 A CMU w
Page 233 and 234:
DESIGN OPTIONS 217 spaces to suppor
Page 235 and 236:
DESIGN OPTIONS 219 FIGURE 12 The wa
Page 237 and 238:
DESIGN OPTIONS 221 FIGURE 15 Severa
Page 239 and 240:
to the facility. IEST - RP - CC006
Page 241 and 242:
CONSTRUCTION PHASE: CLEAN BUILD PRO
Page 243 and 244:
APPENDIX A 227 and storage space fo
Page 245 and 246:
APPENDIX A 229 closed at the neck,
Page 247 and 248:
I. The HEPA fi lter protective fi l
Page 249:
SECTION 4 NORMAL DOSAGE FORMS
Page 252 and 253:
236 SOLID DOSAGE FORMS 4.1.9 Chewab
Page 254 and 255:
238 SOLID DOSAGE FORMS A dose solub
Page 256 and 257:
240 SOLID DOSAGE FORMS TABLE 3 Exci
Page 258 and 259:
242 SOLID DOSAGE FORMS Antiadherent
Page 260 and 261:
244 SOLID DOSAGE FORMS Despite the
Page 262 and 263:
246 SOLID DOSAGE FORMS TABLE 4 Poly
Page 264 and 265:
248 SOLID DOSAGE FORMS TABLE 5 Caps
Page 266 and 267:
250 SOLID DOSAGE FORMS of both. Sof
Page 268 and 269:
252 SOLID DOSAGE FORMS reaction in
Page 270 and 271:
254 SOLID DOSAGE FORMS to a rapid o
Page 272 and 273:
256 SOLID DOSAGE FORMS TABLE 8 Typi
Page 274 and 275:
258 SOLID DOSAGE FORMS Piston Base
Page 276 and 277:
260 SOLID DOSAGE FORMS TABLE 10 Exa
Page 278 and 279:
262 SOLID DOSAGE FORMS pressures du
Page 280 and 281:
264 SOLID DOSAGE FORMS 12. The Unit
Page 283 and 284:
4.2 SEMISOLID DOSAGES: OINTMENTS, C
Page 285 and 286:
OINTMENTS AND CREAMS 269 bases), ab
Page 287 and 288:
OINTMENTS AND CREAMS 271 compendial
Page 289 and 290:
TABLE 2 Properties of Different Gra
Page 291 and 292:
OINTMENTS AND CREAMS 275 Preparatio
Page 293 and 294:
OINTMENTS AND CREAMS 277 TABLE 3 Cr
Page 295 and 296:
OINTMENTS AND CREAMS 279 FIGURE 1 S
Page 297 and 298:
TABLE 4 Drug Acyclovir Alclometason
Page 299 and 300:
OINTMENTS AND CREAMS 283 Packaging
Page 301 and 302:
OINTMENTS AND CREAMS 285 presence o
Page 303 and 304:
OINTMENTS AND CREAMS 287 side and s
Page 305 and 306:
TABLE 6 a Drug Acyclovir Atropine s
Page 307 and 308:
TABLE 7 Continued Commercial Produc
Page 309 and 310:
GELS 293 (e.g., carbomers) that con
Page 311 and 312:
GELS 295 molecular weight, gelling
Page 313 and 314:
GELS 297 Ethylcellulose Ethylcellul
Page 315 and 316:
GELS 299 practically insoluble in w
Page 317 and 318:
GELS 301 out takes place. The visco
Page 319 and 320:
GELS 303 FIGURE 3 Vacuum processing
Page 321 and 322:
GELS 305 chramatograph for quantita
Page 323 and 324:
TABLE 10 a Drug Benzocaine Benzoyl
Page 325 and 326:
TABLE 11 Continued Type of Change C
Page 327 and 328:
REFERENCES 311 8. Fisher , A. A. (
Page 329 and 330:
4.3 LIQUID DOSAGE FORMS Maria V. Ru
Page 331 and 332:
are both challenges and opportuniti
Page 333 and 334:
GENERALITIES 317 that are more deci
Page 335 and 336:
APPROACHES 319 To apply QbD as a sy
Page 337 and 338:
CRITICAL ASPECTS OF LIQUIDS MANUFAC
Page 339 and 340:
Dosing Pumps Collector Tank Continu
Page 341 and 342:
Page 343 and 344:
Page 345 and 346:
Page 347 and 348:
Page 349 and 350:
Page 351 and 352:
Page 353 and 354:
Page 355 and 356:
LIQUID DOSAGE FORMS 339 For Solutio
Page 357 and 358:
Suspension, Extended Release A liqu
Page 359 and 360:
REFERENCES 343 26. Guides to inspec
Page 361:
SECTION 5 SPECIAL/NEW DOSAGE FORMS
Page 364 and 365:
348 CONTROLLED-RELEASE DOSAGE FORMS
Page 366 and 367:
Page 368 and 369:
Page 370 and 371:
Page 372 and 373:
Page 374 and 375:
Page 376 and 377:
Page 378 and 379:
Page 380 and 381:
Page 382 and 383:
Page 384 and 385:
Page 386 and 387:
Page 388 and 389:
Page 390 and 391:
Page 392 and 393:
Page 394 and 395:
Page 396 and 397:
Page 398 and 399:
Page 400 and 401:
Page 402 and 403:
Page 404 and 405:
Page 406 and 407:
Page 408 and 409:
Page 410 and 411:
394 BIODEGRADABLE POLYMER-BASED MIC
Page 412 and 413:
Page 414 and 415:
Page 416 and 417:
Page 418 and 419:
Page 420 and 421:
Page 422 and 423:
Page 424 and 425:
Page 426 and 427:
Page 428 and 429:
Page 430 and 431:
Page 432 and 433:
Page 434 and 435:
Page 436 and 437:
Page 438 and 439:
Page 440 and 441:
Page 442 and 443:
Page 444 and 445:
Page 446 and 447:
Page 448 and 449:
Page 450 and 451:
Page 452 and 453:
Page 454 and 455:
Page 456 and 457:
Page 459 and 460:
5.3 LIPOSOMES AND DRUG DELIVERY Sop
Page 461 and 462:
LIPOSOME STRUCTURE AND CHARACTERIST
Page 463 and 464:
H 2 C O O O - O - - O P O - O P O O
Page 465 and 466:
Page 467 and 468:
Page 469 and 470:
Page 471 and 472:
Page 473 and 474:
In the second approach (probe sonic
Page 475 and 476:
Page 477 and 478:
O R1 SH + N R2 N R2 R 1 Anchor R 2
Page 479 and 480:
Page 481 and 482:
Page 483 and 484:
IN VIVO DISTRIBUTION 467 marrow (du
Page 485 and 486:
IN VIVO DISTRIBUTION 469 absorption
Page 487 and 488:
% injected dose/g % injected dose/g
Page 489 and 490:
IN VIVO DISTRIBUTION 473 combinatio
Page 491 and 492:
IN VIVO DISTRIBUTION 475 delivery i
Page 493 and 494:
IN VIVO DISTRIBUTION 477 increases
Page 495 and 496:
IN VIVO DISTRIBUTION 479 TABLE 3 Ex
Page 497 and 498:
IN VIVO DISTRIBUTION 481 As mention
Page 499 and 500:
TABLE 4 Currently Marketed Liposome
Page 501 and 502:
addition to those existing already,
Page 503 and 504:
Survival (%) 100 75 50 25 APPLICATI
Page 505 and 506:
APPLICATIONS OF LIPOSOMES IN THERAP
Page 507 and 508:
Page 509 and 510:
Page 511 and 512:
μg C 6 / MI Blood Ng C 6 / mg Tumo
Page 513 and 514:
Page 515 and 516:
DXR plasma concentration (μg/mL) 1
Page 517 and 518:
Page 519 and 520:
Page 521 and 522:
Page 523 and 524:
REFERENCES 507 6. Allen , T. M. , a
Page 525 and 526:
REFERENCES 509 42. LeNeveu , D. M.
Page 527 and 528:
REFERENCES 511 78. Frederik , P. M.
Page 529 and 530:
REFERENCES 513 115. Grit , M. , de
Page 531 and 532:
REFERENCES 515 154. Maruyama , K. ,
Page 533 and 534:
REFERENCES 517 185. Schnyder , A. ,
Page 535 and 536:
REFERENCES 519 220. Gregoriadis , G
Page 537 and 538:
REFERENCES 521 254. Shek , P. N. ,
Page 539 and 540:
REFERENCES 523 290. Weiner , N. , W
Page 541 and 542:
REFERENCES 525 328. Torres , P. F.
Page 543 and 544:
REFERENCES 527 A. ( 2004 ), Human i
Page 545 and 546:
REFERENCES 529 393. Fiorillo , A. ,
Page 547 and 548:
REFERENCES 531 423. Paridaens , R.
Page 549:
REFERENCES 533 455. Seiden , M. V.
Page 552 and 553:
536 BIODEGRADABLE NANOPARTICLES 5.4
Page 554 and 555:
538 BIODEGRADABLE NANOPARTICLES Som
Page 556 and 557:
540 BIODEGRADABLE NANOPARTICLES for
Page 558 and 559:
542 BIODEGRADABLE NANOPARTICLES ami
Page 560 and 561:
544 BIODEGRADABLE NANOPARTICLES bot
Page 562 and 563:
546 BIODEGRADABLE NANOPARTICLES Pol
Page 564 and 565:
548 BIODEGRADABLE NANOPARTICLES 99m
Page 566 and 567:
550 BIODEGRADABLE NANOPARTICLES ext
Page 568 and 569:
552 BIODEGRADABLE NANOPARTICLES 5.4
Page 570 and 571:
554 BIODEGRADABLE NANOPARTICLES 14.
Page 572 and 573:
556 BIODEGRADABLE NANOPARTICLES 48.
Page 574 and 575:
558 BIODEGRADABLE NANOPARTICLES Cal
Page 576 and 577:
560 BIODEGRADABLE NANOPARTICLES cop
Page 578 and 579:
562 BIODEGRADABLE NANOPARTICLES 150
Page 580 and 581:
564 BIODEGRADABLE NANOPARTICLES of
Page 582 and 583:
566 IN VITRO VALIDATION AND ORAL FO
Page 584 and 585:
Page 586 and 587:
Page 588 and 589:
Page 590 and 591:
Page 592 and 593:
Page 594 and 595:
Page 596 and 597:
Page 598 and 599:
Page 600 and 601:
Page 602 and 603:
Page 604 and 605:
Page 606 and 607:
Page 608 and 609:
592 NASAL DELIVERY OF PEPTIDE AND N
Page 610 and 611:
Page 612 and 613:
Page 614 and 615:
Page 616 and 617:
Page 618 and 619:
Page 620 and 621:
Page 622 and 623:
Page 624 and 625:
Page 626 and 627:
Page 628 and 629:
Page 630 and 631:
Page 632 and 633:
Page 634 and 635:
Page 636 and 637:
Page 638 and 639:
Page 640 and 641:
Page 642 and 643:
Page 644 and 645:
Page 646 and 647:
Page 648 and 649:
Page 650 and 651:
Page 652 and 653:
Page 654 and 655:
Page 656 and 657:
Page 658 and 659:
Page 660 and 661:
Page 662 and 663:
Page 664 and 665:
Page 666 and 667:
Page 668 and 669:
652 NASAL POWDER DRUG DELIVERY clea
Page 670 and 671:
654 NASAL POWDER DRUG DELIVERY cohe
Page 672 and 673:
656 NASAL POWDER DRUG DELIVERY comb
Page 674 and 675:
658 NASAL POWDER DRUG DELIVERY Its
Page 676 and 677:
660 NASAL POWDER DRUG DELIVERY stud
Page 678 and 679:
662 NASAL POWDER DRUG DELIVERY Chit
Page 680 and 681:
664 NASAL POWDER DRUG DELIVERY PLGA
Page 682 and 683:
666 NASAL POWDER DRUG DELIVERY ties
Page 684 and 685:
668 NASAL POWDER DRUG DELIVERY [124
Page 686 and 687:
TABLE 1 Continued Powder Formulatio
Page 688 and 689:
TABLE 1 Continued Powder Formulatio
Page 690 and 691:
674 NASAL POWDER DRUG DELIVERY REFE
Page 692 and 693:
676 NASAL POWDER DRUG DELIVERY Drug
Page 694 and 695:
678 NASAL POWDER DRUG DELIVERY 72.
Page 696 and 697:
680 NASAL POWDER DRUG DELIVERY 109.
Page 699 and 700:
5.8 AEROSOL DRUG DELIVERY Michael H
Page 701 and 702:
HUMAN RESPIRATORY TRACT AND AEROSOL
Page 703 and 704:
5.8.3 THERAPEUTIC INDICATIONS FOR A
Page 705 and 706:
AEROSOL DRUG DELIVERY DEVICES 689 n
Page 707 and 708:
FIGURE 1 Schematic of MDI. METERED
Page 709 and 710:
TABLE 2 Property METERED DOSE INHAL
Page 711 and 712:
METERED DOSE INHALERS 695 is then c
Page 713 and 714:
METERED DOSE INHALERS 697 the other
Page 715 and 716:
METERED DOSE INHALERS 699 the Easib
Page 717 and 718:
5.8.6.2 Size Reduction and Particle
Page 719 and 720:
DRY POWDER INHALERS 703 recognized
Page 721 and 722:
DRY POWDER INHALERS 705 Spinhaler f
Page 723 and 724:
oken up into droplets by the jet to
Page 725 and 726:
EMERGING TECHNOLOGIES 709 Mouthpiec
Page 727 and 728:
capillary, the formulation is rapid
Page 729 and 730:
REFERENCES 713 22. Kim , C. S. , an
Page 731 and 732:
REFERENCES 715 61. Blanchard , J. D
Page 733 and 734:
REFERENCES 717 100. Dolovich , M. B
Page 735 and 736:
REFERENCES 719 136. Anonymous ( 200
Page 737 and 738:
REFERENCES 721 170. Ward , G. H. ,
Page 739 and 740:
REFERENCES 723 206. Young , P. M. ,
Page 741 and 742:
REFERENCES 725 244. DeFronzo , R. A
Page 743:
REFERENCES 727 280. Schurmann , W.
Page 746 and 747:
730 OCULAR DRUG DELIVERY tissues. T
Page 748 and 749:
732 OCULAR DRUG DELIVERY FIGURE 3 S
Page 750 and 751:
734 OCULAR DRUG DELIVERY melanocyte
Page 752 and 753:
736 OCULAR DRUG DELIVERY represents
Page 754 and 755:
738 OCULAR DRUG DELIVERY TABLE 1 Su
Page 756 and 757:
740 OCULAR DRUG DELIVERY TABLE 1 Co
Page 758 and 759:
742 OCULAR DRUG DELIVERY TABLE 2 Ma
Page 760 and 761:
744 OCULAR DRUG DELIVERY shear - th
Page 762 and 763:
746 OCULAR DRUG DELIVERY 5.9.3.3 Co
Page 764 and 765:
748 OCULAR DRUG DELIVERY tigated in
Page 766 and 767:
750 OCULAR DRUG DELIVERY that w/o M
Page 768 and 769:
752 OCULAR DRUG DELIVERY [138, 232]
Page 770 and 771:
754 OCULAR DRUG DELIVERY Only a few
Page 772 and 773:
756 OCULAR DRUG DELIVERY 32. Schoen
Page 774 and 775:
758 OCULAR DRUG DELIVERY 70. Shibuy
Page 776 and 777:
760 OCULAR DRUG DELIVERY 105. Diepo
Page 778 and 779:
762 OCULAR DRUG DELIVERY 139. Maest
Page 780 and 781:
764 OCULAR DRUG DELIVERY 175. Davie
Page 782 and 783:
766 OCULAR DRUG DELIVERY 213. Law ,
Page 785 and 786:
5.10 MICROEMULSIONS AS DRUG DELIVER
Page 787 and 788:
STRUCTURE AND FORMATION OF MICROEMU
Page 789 and 790:
oily phase, and the interfacial lay
Page 791 and 792:
CHARACTERIZE MICROEMULSIONS AND REL
Page 793 and 794:
CHARACTERIZE MICROEMULSIONS AND REL
Page 795 and 796:
study was conducted on systems comp
Page 797 and 798:
5.10.6.1 Oral Drug Delivery MICROEM
Page 799 and 800:
MICROEMULSIONS AS DRUG DELIVERY SYS
Page 801 and 802:
REFERENCES 785 stability of incorpo
Page 803 and 804:
REFERENCES 787 22. Saint - Ruth , H
Page 805 and 806:
REFERENCES 789 58. Ktistis , G. ( 1
Page 807 and 808:
REFERENCES 791 94. Rhee , Y. S. , C
Page 809 and 810:
5.11 TRANSDERMAL DRUG DELIVERY C. S
Page 811 and 812:
Drug plasma concentration FIGURE 1
Page 813 and 814:
PHYSIOLOGY AND CHARACTERISTICS OF H
Page 815 and 816:
Another important parameter when se
Page 817 and 818:
COMMERCIALLY AVAILABLE PATCHES 801
Page 819 and 820:
5.11.8.1 Chemical Penetration Enhan
Page 821 and 822:
corneum much like the microneedle t
Page 823:
REFERENCES 807 40. Mitragotri , S.
Page 826 and 827:
810 VAGINAL DRUG DELIVERY 5.12.5.6
Page 828 and 829:
812 VAGINAL DRUG DELIVERY The vagin
Page 830 and 831:
814 VAGINAL DRUG DELIVERY have mucu
Page 832 and 833:
816 VAGINAL DRUG DELIVERY TABLE 1 C
Page 834 and 835:
818 VAGINAL DRUG DELIVERY Menopausa
Page 836 and 837:
820 VAGINAL DRUG DELIVERY 500 400 3
Page 838 and 839:
822 VAGINAL DRUG DELIVERY spreadabi
Page 840 and 841:
824 VAGINAL DRUG DELIVERY distribut
Page 842 and 843:
826 VAGINAL DRUG DELIVERY improved
Page 844 and 845:
828 VAGINAL DRUG DELIVERY FIGURE 4
Page 846 and 847:
Page 848 and 849:
Page 850 and 851:
834 VAGINAL DRUG DELIVERY availabil
Page 852 and 853:
Page 854 and 855:
838 VAGINAL DRUG DELIVERY results.
Page 856 and 857:
Page 858 and 859:
842 VAGINAL DRUG DELIVERY studies t
Page 860 and 861:
844 VAGINAL DRUG DELIVERY subject i
Page 862 and 863:
846 VAGINAL DRUG DELIVERY formulati
Page 864 and 865:
Page 866 and 867:
850 VAGINAL DRUG DELIVERY shown to
Page 868 and 869:
852 VAGINAL DRUG DELIVERY poloxamer
Page 870 and 871:
854 VAGINAL DRUG DELIVERY made. Ide
Page 872 and 873:
Page 874 and 875:
858 VAGINAL DRUG DELIVERY 13. Wagne
Page 876 and 877:
860 VAGINAL DRUG DELIVERY 54. Corbo
Page 878 and 879:
862 VAGINAL DRUG DELIVERY supposito
Page 880 and 881:
864 VAGINAL DRUG DELIVERY 123. van
Page 882 and 883:
866 VAGINAL DRUG DELIVERY nanospher
Page 884 and 885:
868 VAGINAL DRUG DELIVERY 196. Jone
Page 886 and 887:
870 VAGINAL DRUG DELIVERY Irritatio
Page 888 and 889:
872 VAGINAL DRUG DELIVERY 261. Czei
Page 890 and 891:
874 VAGINAL DRUG DELIVERY 293. Fowl
Page 892 and 893:
876 VAGINAL DRUG DELIVERY 327. O
Page 894 and 895:
878 VAGINAL DRUG DELIVERY 359. Rath
Page 897 and 898:
6.1 PHARMACEUTICAL PREFORMULATION:
Page 899 and 900:
tion. According to global Internati
Page 901 and 902:
SELECTION OF PHARMACEUTICAL EXCIPIE
Page 903 and 904:
Page 905 and 906:
TABLE 4 Disintegrant Starch Commonl
Page 907 and 908:
Page 909 and 910:
Page 911 and 912:
Page 913 and 914:
DRUG-EXCIPIENT COMPATIBILITY 897 ap
Page 915 and 916:
DRUG-EXCIPIENT COMPATIBILITY 899 in
Page 917 and 918:
POWDER CHARACTERISTICS 901 their im
Page 919 and 920:
POWDER CHARACTERISTICS 903 TABLE 13
Page 921 and 922:
POWDER CHARACTERISTICS 905 Microsco
Page 923 and 924:
Powder flow rate FIGURE 6 No flow b
Page 925 and 926:
POWDER CHARACTERISTICS 909 Measurem
Page 927 and 928:
V − V ε= V b p b V = 1− V POWD
Page 929 and 930:
POWDER CHARACTERISTICS 913 The mois
Page 931 and 932:
Tensile strength (Pa) 14 12 10 8 6
Page 933 and 934:
POWDER CHARACTERISTICS 917 and poor
Page 935 and 936:
infl uence the physicochemical prop
Page 937 and 938:
Tablet disintegration is the import
Page 939 and 940:
ability studies and from human stud
Page 941 and 942:
Variables Affecting Dissolution In
Page 943 and 944:
TABLET CHARACTERIZATION 927 The dif
Page 945 and 946:
The requirements for content unifor
Page 947:
REFERENCES 931 15. Simon , P. , Vev
Page 950 and 951:
934 ROLE OF PREFORMULATION IN DEVEL
Page 952 and 953:
Page 954 and 955:
Page 956 and 957:
Page 958 and 959:
Page 960 and 961:
Page 962 and 963:
Page 964 and 965:
Page 966 and 967:
Page 968 and 969:
Page 970 and 971:
Page 972 and 973:
Page 974 and 975:
Page 976 and 977:
Page 978 and 979:
Page 980 and 981:
Page 982 and 983:
Page 984 and 985:
Page 986 and 987:
Page 988 and 989:
Page 990 and 991:
Page 993 and 994:
6.3 TABLET DESIGN Eddy Castellanos
Page 995 and 996:
TABLETING CYCLE 979 The eccentric p
Page 997 and 998:
FIGURE 4 (a) (b) (c) TABLETING CYCL
Page 999 and 1000:
TABLE 1 mm 3 4 5 6 7 8 9 10 11 12 1
Page 1001 and 1002:
LIMITATIONS FOR DIRECT COMPRESSION
Page 1003 and 1004:
Drug release (%) 120 100 80 60 40 2
Page 1005 and 1006:
Beta Carotene Tablets (15 mg ) Form
Page 1007 and 1008:
Lisinopril release (%) FIGURE 10 BI
Page 1009 and 1010:
that do not compress well after wet
Page 1011 and 1012:
Calcium phosphate, dibasic offers h
Page 1013 and 1014:
FIGURE 11 Theophylline release (%)
Page 1015 and 1016:
TABLET DESIGN WITH NATURAL PRODUCTS
Page 1017 and 1018:
TABLE 7 Two Formulations for mangif
Page 1019 and 1020:
TABLE 8 Weight Assay Disintegration
Page 1021 and 1022:
TABLET DESIGN WITH NATURAL PRODUCTS
Page 1023 and 1024:
has a regulatory effect upon the an
Page 1025 and 1026:
DESIGN TOOLS OF TABLET FORMULATION
Page 1027 and 1028:
Amount released PPL (%) 110 100 90
Page 1029 and 1030:
DESIGN TOOLS OF TABLET FORMULATION
Page 1031 and 1032:
Percolation threshold (ε c) FIGURE
Page 1033 and 1034:
6.3.8 COATING SYSTEMS COATING SYSTE
Page 1035 and 1036:
COATING SYSTEMS 1019 ences between
Page 1037 and 1038:
Water absorption, % 8 7 6 5 4 3 2 1
Page 1039 and 1040:
FIGURE 28 white. mg/h·m 0.9 0.8 0.
Page 1041 and 1042:
(a) (b) FIGURE 31 ( a ) Tablet coat
Page 1043 and 1044:
TABLE 18 Solid content Batch size,
Page 1045 and 1046:
Percent released FIGURE 35 Tablet b
Page 1047 and 1048:
PHARMACEUTICAL TABLETS USING PERCOL
Page 1049 and 1050:
TABLE 23 Calculation of Tablet Prop
Page 1051 and 1052:
Page 1053 and 1054:
Page 1055 and 1056:
TABLE 25 Aspect Ratios and Exponent
Page 1057 and 1058:
K H (%min - 1/2)/% v/v excipient pl
Page 1059 and 1060:
6.3.10 ULTRASOUND-ASSISTED TABLETIN
Page 1061 and 1062:
ULTRASOUND-ASSISTED TABLETING (A NE
Page 1063 and 1064:
REFERENCES 1047 18. S á nchez , G.
Page 1065 and 1066:
REFERENCES 1049 54. Hess , H. , and
Page 1067:
92. Mill á n , M. , and Caraballo
Page 1070 and 1071:
1054 TABLET PRODUCTION SYSTEMS 6.4.
Page 1072 and 1073:
1056 TABLET PRODUCTION SYSTEMS comp
Page 1074 and 1075:
1058 TABLET PRODUCTION SYSTEMS and
Page 1076 and 1077:
1060 TABLET PRODUCTION SYSTEMS FIGU
Page 1078 and 1079:
Page 1080 and 1081:
Page 1082 and 1083:
1066 TABLET PRODUCTION SYSTEMS when
Page 1084 and 1085:
1068 TABLET PRODUCTION SYSTEMS die
Page 1086 and 1087:
Page 1088 and 1089:
1072 TABLET PRODUCTION SYSTEMS TABL
Page 1090 and 1091:
1074 TABLET PRODUCTION SYSTEMS Pres
Page 1092 and 1093:
1076 TABLET PRODUCTION SYSTEMS Forc
Page 1094 and 1095:
1078 TABLET PRODUCTION SYSTEMS In(1
Page 1096 and 1097:
1080 TABLET PRODUCTION SYSTEMS In[1
Page 1098 and 1099:
1082 TABLET PRODUCTION SYSTEMS [78,
Page 1100 and 1101:
Page 1102 and 1103:
1086 TABLET PRODUCTION SYSTEMS When
Page 1104 and 1105:
1088 TABLET PRODUCTION SYSTEMS 3. P
Page 1106 and 1107:
1090 TABLET PRODUCTION SYSTEMS 44.
Page 1108 and 1109:
Page 1110 and 1111:
Page 1112 and 1113:
Page 1114 and 1115:
Page 1116 and 1117:
1100 CONTROLLED RELEASE OF DRUGS FR
Page 1118 and 1119:
Page 1120 and 1121:
Page 1122 and 1123:
Page 1124 and 1125:
Page 1126 and 1127:
Page 1128 and 1129:
Page 1130 and 1131:
Page 1132 and 1133:
Page 1134 and 1135:
Page 1136 and 1137:
Page 1138 and 1139:
Page 1140 and 1141:
Page 1142 and 1143:
Page 1144 and 1145:
Page 1146 and 1147:
Page 1148 and 1149:
Page 1150 and 1151:
1134 TABLET COMPRESSION stages invo
Page 1152 and 1153:
1136 TABLET COMPRESSION although on
Page 1154 and 1155:
1138 TABLET COMPRESSION P P = + C a
Page 1156 and 1157:
1140 TABLET COMPRESSION 4. Estimati
Page 1158 and 1159:
1142 TABLET COMPRESSION from a hopp
Page 1160 and 1161:
1144 TABLET COMPRESSION speed of th
Page 1162 and 1163:
1146 TABLET COMPRESSION FIGURE 4 Co
Page 1164 and 1165:
1148 TABLET COMPRESSION FIGURE 5 Id
Page 1166 and 1167:
1150 TABLET COMPRESSION its low tou
Page 1168 and 1169:
1152 TABLET COMPRESSION Standard TS
Page 1170 and 1171:
1154 TABLET COMPRESSION A B C D E F
Page 1172 and 1173:
1156 TABLET COMPRESSION Top view Pr
Page 1174 and 1175:
1158 TABLET COMPRESSION particle si
Page 1176 and 1177:
1160 TABLET COMPRESSION 6.6.10.3 Mo
Page 1178 and 1179:
1162 TABLET COMPRESSION 7. Masteau
Page 1181 and 1182:
6.7 EFFECTS OF GRINDING IN PHARMACE
Page 1183 and 1184:
MILLING EQUIPMENT 1167 whereas smal
Page 1185 and 1186:
Screen Product FIGURE 3 Hammers Ham
Page 1187 and 1188:
inders, disintegrants, glidants, lu
Page 1189 and 1190:
Airflow Press POWDER CHARACTERIZATI
Page 1191 and 1192:
Powder flow Sample Process stream (
Page 1193 and 1194:
Container 1 Container 1 Discard (a)
Page 1195 and 1196:
Porous particles in container POWDE
Page 1197 and 1198:
POWDER CHARACTERIZATION TECHNIQUES
Page 1199 and 1200:
expansions or fractal dimensions);
Page 1201 and 1202:
EFFECT OF PARTICLE SIZE REDUCTION O
Page 1203 and 1204:
EFFECT OF PARTICLE SIZE REDUCTION O
Page 1205 and 1206:
REFERENCES 1189 19. British Standar
Page 1207 and 1208:
6.8 ORAL EXTENDED - RELEASE FORMULA
Page 1209 and 1210:
INTRODUCTION 1193 line) together wi
Page 1211 and 1212:
INTRODUCTION 1195 substance) instea
Page 1213 and 1214:
of the drug particles/formulation a
Page 1215 and 1216:
M A DCt t = ⎡ ε s ( 2C − C )
Page 1217 and 1218:
method for insoluble matrix tablets
Page 1219 and 1220:
MEMBRANE-COATED ORAL EXTENDED RELEA
Page 1221 and 1222:
MEMBRANE-COATED ORAL EXTENDED RELEA
Page 1223 and 1224:
Swelling front Diffusion front Eros
Page 1225 and 1226:
dM Q = ∫ dt = kt 0 dt HYDROPHILIC
Page 1227 and 1228:
TABLE 2 FDA Registered Oral ER Form
Page 1229 and 1230:
6.8.6 OTHER ORAL ER FORMULATIONS OT
Page 1231 and 1232:
REFERENCES 1215 15. Neau , S. H. ,
Page 1233 and 1234:
REFERENCES 1217 54. Sousa , J. J. ,
Page 1235 and 1236:
REFERENCES 1219 89. Ford , J. L. ,
Page 1237 and 1238:
REFERENCES 1221 122. Talukdar , M.
Page 1239:
SECTION 7 ROLE OF NANOTECHNOLOGY
Page 1242 and 1243:
1226 CYCLODEXTRIN-BASED NANOMATERIA
Page 1244 and 1245:
Page 1246 and 1247:
Page 1248 and 1249:
Page 1250 and 1251:
Page 1252 and 1253:
Page 1254 and 1255:
Page 1256 and 1257:
Page 1258 and 1259:
Page 1260 and 1261:
Page 1262 and 1263:
Page 1265 and 1266:
7.2 NANOTECHNOLOGY IN PHARMACEUTICA
Page 1267 and 1268:
NANOMATERIALS 1251 tists regard mat
Page 1269 and 1270:
NANOMATERIALS 1253 TABLE 1 Characte
Page 1271 and 1272:
NANOMATERIALS 1255 sor molecules/pa
Page 1273 and 1274:
TABLE 2 Continued Types of Nanomate
Page 1275 and 1276:
H 3 C CH 3 N + CH 3 O O O O - P O O
Page 1277 and 1278:
NANOTECHNOLOGY FOR DRUG DELIVERY 12
Page 1279 and 1280:
entrapped drugs releasing [90] . So
Page 1281 and 1282:
Page 1283 and 1284:
Page 1285 and 1286:
Page 1287 and 1288:
Page 1289 and 1290:
Page 1291 and 1292:
Page 1293 and 1294:
Page 1295 and 1296:
NANOMEDICINE 1279 prises) visibly p
Page 1297 and 1298:
REFERENCES 1281 16. http://www.whit
Page 1299 and 1300:
REFERENCES 1283 55. Kam , N. W. S.
Page 1301 and 1302:
REFERENCES 1285 92. Zhang , J. Q. ,
Page 1303 and 1304:
REFERENCES 1287 126. Smart , S. K.
Page 1305 and 1306:
7.3 PHARMACEUTICAL NANOSYSTEMS: MAN
Page 1307 and 1308:
7.3.2 TAXONOMY OF NANOMEDICINE TECH
Page 1309 and 1310:
TABLE 1 Continued Molecular medicin
Page 1311 and 1312:
Applications of quantum dots includ
Page 1313 and 1314:
7.3.5 MANUFACTURING TECHNOLOGIES Th
Page 1315 and 1316:
Ratio of hydrodynamic radius, R H ,
Page 1317 and 1318:
eplicated on the substrate, with na
Page 1319 and 1320:
MANUFACTURING TECHNOLOGIES 1303 bel
Page 1321 and 1322:
CHARACTERIZATION TECHNIQUES 1305 TA
Page 1323 and 1324:
CHARACTERIZATION TECHNIQUES 1307 TA
Page 1325 and 1326:
Limitations of AFM [255 - 257] Pote
Page 1327 and 1328:
REFERENCES 1311 thelial cells, the
Page 1329 and 1330:
REFERENCES 1313 34. Ostrander , K.
Page 1331 and 1332:
REFERENCES 1315 77. Muangsiri , W.
Page 1333 and 1334:
REFERENCES 1317 124. Caruso , F. ,
Page 1335 and 1336:
REFERENCES 1319 170. Rogers , J. A.
Page 1337 and 1338:
REFERENCES 1321 application: Synthe
Page 1339 and 1340:
252. Fontaine , P. A. , et al. ( 19
Page 1341:
Characterization Methods Binks , B.
Page 1344 and 1345:
1328 OIL-IN-WATER NANOSIZED EMULSIO
Page 1346 and 1347:
Page 1348 and 1349:
1332 Application TABLE 1 Selected M
Page 1350 and 1351:
Page 1352 and 1353:
Page 1354 and 1355:
Page 1356 and 1357:
Page 1358 and 1359:
Page 1360 and 1361:
Page 1362 and 1363:
Page 1364 and 1365:
Page 1366 and 1367:
Page 1368 and 1369:
Page 1370 and 1371:
Page 1372 and 1373:
Page 1374 and 1375:
Page 1376 and 1377:
Page 1378 and 1379:
Page 1380 and 1381:
Page 1382 and 1383:
Page 1384 and 1385:
1368 INDEX Cholera toxin, 637 Cilio
Page 1386:
1370 INDEX Production of radiopharm
show all

Pharmaceutical Manufacturing Handbook: Production and

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?